Using Artificial Intelligence to Improve Patient Adherence Results and Patient Outcomes
Dr. Andrée Bates
Chairman/Founder/CEO @ Eularis | AI Pharma Expert, Keynote Speaker | Our pharma clients achieve measurable exponential growth in efficiency and revenue from leveraging AI | Investor
Pharmaceutical companies spend a significant percentage of their marketing budgets to capture initial market share. Since the majority of spend goes towards attracting new customer, efforts at retaining existing customers are given short shrift, with a paltry percent of budgets focused on these. By focusing mostly on new customers, companies are missing a valuable opportunity to increase sales and market share.
Impact of lack of adherence on Patients
Overall, non-adherence is responsible for an estimated 125,000 deaths a year in the United States, 33 to 69 percent of medication-related hospital admissions, and nearly 23 percent of all nursing home admissions. It is also a significant factor in drug-resistant infections such as HIV and antibiotic-resistant infections, posing both an individual and a public health risk.
Numerous studies find that patients who follow treatment recommendations have better health outcomes than those who don’t. One, Horwitz et al., found patients who took 75 percent or less of the recommended dosage of beta blockers following a myocardial infarction were two to six times more likely than more adherent patients to die within a year of follow up.
Impact of lack of adherence on Physicians
Non-adherence affects a physician’s ability to appropriately treat patients. For instance, if a patient is non-adherent or only partially adherent to prescribed medication and symptoms continue, physicians may assume a drug is not working and switch the patient to another medication. This can adversely affect the efficacy of a particular treatment regimen and may hurt the patient’s chances at improving.
Physicians feel the negative effects of non-adherence in other ways. With high compliance comes less disease-related medical costs for patients, fewer complications and less need for extensive visits or emergency hospital visits. However, with low compliance comes increased complications and hospitalization. In a study of diabetes patients, those who were 80-100 percent adherent had a low risk of hospitalization (13 percent). When adherence dropped to 60-79 percent, risk increased to 20 percent. A drop in adherence down to 40-59 percent saw another jump in hospitalization risk, to 24 percent. Patients’ who are non-adherent have more problems, problems physicians may not be able to accurately diagnose, understand and treat.
Impact of lack of adherence on Pharma
In todays’ cost constrained world, pharmaceutical companies can no longer ignore the hidden value available by increasing patient adherence. Today, an estimated 70 percent of patients who begin a Pharmaceutical therapy discontinue it within 1 year, even those with chronic conditions that require ongoing treatment or those taking chemotherapy to prevent cancer recurrence. This costs the global Pharmaceutical Industry an estimated $30 Billion a year.
Put another way, increased adherence for a product with approximately $1 Billion in sales would translate to an additional $30 to $40 Million in annual revenue. In addition, since it costs six times more to attract new patients than to retain current patients, increasing the focus on, and yields from, adherence means additional money saved and earned.
The Solution: Using Artificial Intelligence to Predict and Enhance Outcomes
Companies implement numerous strategies to increase adherence and persistence with their products that have varying success as lack of adherence has many causes (over 250 have been documented in one study).
However, now with Artificial Intelligence techniques we have even more powerful approaches that allow stronger predictive insights that allow companies to predict which patients will cease therapies and what specific interventions will keep them on their treatment.
Getting data on our customers allows us many types of insights.
One project that we have done several times for various pharma clients in the patient adherence space is analyzing at patient data and identifying which individual patients will stop adhering to treatment in advance of them doing so, and then identifying what it would take to prevent them stopping treatment where this is medically indicated. Of course, if it is due to severe side effects or a medical reason for ceasing that treatment, then that is sensible and would not be indicated for intervention.
The great thing about the clients we have had in this space to date is that they have a wealth of patient data because of the support they are providing their patients with nurse support and brand ambassadors which can greatly assist the implementation of the personalized insights for patient adherence on the brand. We have patient notes from the visiting nurses who help them with their injections, we have delivery information about the drugs and when they are delivered to the patients, we have call center interactions from the patients and their point of contact. We even have sensor data from the needles themselves. And a lot more. Then we apply a combination of Natural Language Processing Algorithms and Machine Learning algorithms to the combined data in order to identify who will stop adherence, why, and what interventions would change the result and keep them adhering to their medications. This is fed automatically into a system for the nurses seeing the patients so each day they could see which patients were in danger and what interventions would be most effective, as well as to the patient liaison in the call centers. The brand team also get summaries of how many are currently predicted to cease treatment, and heat maps of where they are, and results of interventions in terms of staying on therapy.
The projects we have done in this space have been very successful when comparing the percentage of patients who ceased treatment before the algorithms to the percentage doing so after the systems have been introduced and therefore have improved patient outcomes and improved our client’s revenue.of
Conclusion
Big data and AI allows the solving of numerous challenges within pharma but this particular one is a very important one when one considers the outcomes for patients who cease taking treatment when they should not.
领英推荐
P.S. Here are?5?ways we can help you accelerate your?Pharma AI?results:
Dr Bates posts regularly about AI in Pharma so if you follow her you will get even more insights.
? ? ? ? ?Here is the Spotify link
? ? ? ? ?Here is the Apple link
Revolutionize your team’s AI solution vendor choice process and unlock unparalleled efficiency and save millions on poor AI vendor choices that are not meeting your needs! Stop wasting precious time sifting through countless vendors and gain instant access to a curated list of top-tier companies, expertly vetted by leading pharma AI experts.
Every year, we rigorously interview thousands of AI companies that tackle pharma challenges head-on. Our comprehensive evaluations cover whether the solution delivers what is needed, their client results, their AI sophistication, cost-benefit ratio, demos, and more. We provide an exclusive, dynamic database, updated weekly, brimming with the best AI vendors for every business unit and challenge. Plus, our cutting-edge AI technology makes searching it by business unit, challenge, vendors or demo videos and information a breeze.
Transform your AI strategy with our expertly curated vendors that walk the talk, and stay ahead in the fast-paced world of pharma AI!
Get on the wait list to access this today.?Click here.
When we analysed the most successful AI in biopharma and their agencies, we found there are very specific strategies that deliver the most consistent results year after year. This assessment is designed to give clarity as to how to achieve a successful outcome from AI.
The first step is to?complete this short questionnaire, it will give us the information to assess which process is right for you as a next step.
It’s free and obligation-free, so go ahead and complete it now. Plus receive a free link to our a free AI tools pdf and our 5 day training (30 mins a day) in AI in pharma.??Link to assessment here.?
We have created an in-depth on-demand training about AI specifically for pharma that translate it into easy understanding of AI and how to apply it in all the different pharma business units —?Click here to find out more.
President at Morse Design | Devotee of Arts and Humanity
1 个月Transformational Potential ????
Artificial Intelligence at the US FDA
1 个月Great post! Adherence is critical to treatment success. The MMAS (Morisky Medication Adherence Scale) can be leveraged with AI/ML in order to perform predictive analytics that can then inform patients and physicians on regimens and really push Adherence into the next generation!
Strategist | Fractional Chief of Staff & Advisor | Competitive & Market Intel | Writer
1 个月Steve Waddell, MBA, PMP??
Creating objective measures for ADHD and brain health
1 个月Thank you for sharing this important information. I think that collecting the data and understanding the true cause is super important. One aspect that is often overlooked is that many patients with chronic diseases deal with other challenges in life. Often caring for other sick family members, as some fo these conditions are genetic. Another aspect has to do with the patient's mental health. There is a connection between mental and physical health (not researched enough). One condition that makes following up on routines especially challenging is ADHD. The cost of not treating ADHD includes the health cost of non-adherence.
Chief Optimus at Adherence | ai and mL Morisky Medication Adherence Scales | MMAS-4 MMAS-8
1 个月Very relevant and exactly what we are doing here at Adherence. Using our validated and standardized questions, adding ai and ml to the protocol enhances the conversation that forms true, long term behavioral change. It has already been documented in studies around the world that pharmacist or nurse led interventions actually improve adherence. Our approach provides an actual scoring method that follows a patient over time, and ai takes the conversation further. Non adherence can be divided between intentional and unintentional. Focusing on the reasons for non adherence identifies the specific barriers that patients face, and then we can offer tailored and individualized solutions. Remote patient monitoring and reduced readmissions is now much more effective when the health care system already knows which patients are at risk for non adherence.